Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
57 pending office actions • 40 clients • 54 examiners • 35 art units • 0 of 57 (0%) have an AI response strategy ready
MORSE, BARNES-BROWN & PENDLETON, P.C. operates as a patent law firm in Biotechnology & Pharmaceuticals. The firm has handled 2365 career applications, resulting in a resolved allowance rate of 82.06 percent. Prosecution at the firm averages 3.64 office actions per allowance.
There are 48 pending office actions currently under management. The 3.64 average office actions per allowance reflects the typical intensity of prosecution in the Biotechnology & Pharmaceuticals sector. This data is based on 2365 career applications, providing a solid foundation for performance analysis.
The 82.06 percent allowance rate indicates a strong success rate for resolved applications. Practitioners can use the 3.64 average office actions per allowance to estimate the typical duration of the prosecution process. The 48 pending office actions represent the firm's current active workload in this technology area.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 4 (7%) |
| §103 only | 17 (30%) |
| §102 only | 3 (5%) |
| §112 only | 4 (7%) |
| Double-patenting + other | 4 (7%) |
| Multi-statute (no §101) | 24 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 2 | 67.0% | +39.9% |
| HUDSON, AMY ROSE | 2 | 74.9% | +11.5% |
| PERREIRA, MELISSA JEAN | 2 | 52.0% | +25.8% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| REYES, EDGAR | 1 | 37.0% | +29.4% |
| YABUT, DIANE D | 1 | 62.5% | +27.9% |
| DUBOSE, LAUREN | 1 | 60.1% | +43.3% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18135773 | PATCH SYSTEM FOR MONITORING AND ENHANCING SLEEP AND CIRCADIAN RHYTHM ALIGNMENT | DORNA, CARRIE R | 60d overdue |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | GROSS, CHRISTOPHER M | 53d overdue |
| 18023086 | METHODS OF PREPARING IRON COMPLEXES | SAEED, ALI S | 23d overdue |
| 17783573 | ALDH3A2 INHIBITION AND FERROPTOSIS INDUCTION FOR CANCER THERAPY | HUDSON, AMY ROSE | 29d |
| 18949619 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | SINGH, ANOOP KUMAR | 34d |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18701596 | OPTIMIZED BIOSYNTHESIS PATHWAY FOR CANNABINOID BIOSYNTHESIS | LOUNTOS, GEORGE THEMISTOCLIS | 84d |
| 18560883 | ENGINEERED CELLS, ENZYMES, AND METHODS FOR PRODUCING CANNABINOIDS | GORDON, MELENIE LEE | 84d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040967 | METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES | PERREIRA, MELISSA JEAN | 16d |
| 17783573 | ALDH3A2 INHIBITION AND FERROPTOSIS INDUCTION FOR CANCER THERAPY | HUDSON, AMY ROSE | 29d |
| 18949619 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | SINGH, ANOOP KUMAR | 34d |
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | — |
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | — |
| 19329089 | A HYDROPONIC SYSTEM, AND A PROCESS FOR PRODUCING A HYDROPONIC SYSTEM | REYES, EDGAR | — |
| 19051958 | PERSONALIZED-FIT NASAL DILATOR | YABUT, DIANE D | — |
| Art Unit | Apps |
|---|---|
| 1632 | 5 |
| 1638 | 2 |
| 1682 | 2 |
| 1612 | 2 |
| 1684 | 2 |
| 1654 | 2 |
| 1637 | 2 |
| 1623 | 2 |
| 1636 | 2 |
| 1618 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | Renabio Therapeutics, Inc. | JOHNSON, ALLISON MARIE | 1638 | §102Other | Non-Final OA | — | Pending | Jan 14, 2026 |
| 19407141 | LIGAND-DRUG CONJUGATES | Tripartite Therapeutics Inc. | PUTTLITZ, KARL J | 1646 | §102§112Other | Final Rejection | — | Pending | Dec 03, 2025 |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | DANA-FARBER CANCER INSTITUTE, INC. | MYERS, CARLA J | 1682 | §101§102§103§112DP | Final Rejection | — | Pending | Nov 21, 2025 |
| 19329089 | A HYDROPONIC SYSTEM, AND A PROCESS FOR PRODUCING A HYDROPONIC SYSTEM | Ellepot A/S | REYES, EDGAR | 3642 | §103 | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19051958 | PERSONALIZED-FIT NASAL DILATOR | Breathewave Technologies Inc. | YABUT, DIANE D | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2025 | |
| 18968750 | CONTOUR-FIT NASAL DILATOR | Breathewave Technologies Inc. | DUBOSE, LAUREN | 3771 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18949619 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | President and Fellows of Harvard College | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | 34d | Pending | Nov 15, 2024 |
| 18861916 | AN APPARATUS PROVIDING COOLING OF SEAWATER SURFACES COMPRISING A BUBBLE CURTAIIN | Oceantherm AS | FIORELLO, BENJAMIN F | 3678 | §102§103§112 | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18916572 | REPROGRAMMING OF SOMATIC CELLS | Whitehead Institute For Biomedical Research | NOBLE, MARCIA STEPHENS | §103§112 | Non-Final OA | — | Pending | Oct 15, 2024 | |
| 18907240 | METHOD FOR EFFICIENT DRUG ADMINISTRATION ACROSS THE BLOOD-BRAIN BARRIER AND USES THEREOF | Carthera | MATTSON, SEAN D | 3798 | §103 | Final Rejection | — | Pending | Oct 04, 2024 |
| 18885174 | MOBILE INFRARED AND NEGATIVE OXYGEN ION EXPOSURE CHAMBER | Henan Qianpeng Biopharmaceutical Co. Ltd. | MOON, MATTHEW RYAN | §103 | Non-Final OA | — | Pending | Sep 13, 2024 | |
| 18845476 | INDUCED TOTIPOTENT POTENTIAL STEM CELLS, METHODS OF MAKING AND USING | Peking University | KASAYAN, KATRIEL BARCELLANO | §101§103§112 | Non-Final OA | — | Pending | Sep 10, 2024 | |
| 18832837 | A METHOD OF FORMING A COMPOSITION COMPRISING A PROBIOTIC MICRO-ENCAPSULATED IN A DENATURED PLANT PROTEIN MATRIX | Anabio Technologies Ltd. | WEBB, WALTER E | 1612 | §102§103 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18773428 | METHODS OF EDITING DNA METHYLATION | Whitehead Institute For Biomedical Research | LEE, JAE W | §103§112 | Non-Final OA | — | Pending | Jul 15, 2024 | |
| 18755632 | PHOSPHORESCENT AUTHENTICATION DEVICES, SYSTEMS, AND METHODS | Spectra Systems Corporation | LEE, SHUN K | 2884 | §103 | Non-Final OA | 84d | Pending | Jun 26, 2024 |
| 18742930 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | President and Fellows of Harvard College | JOHNSON, KARA D | §103 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18742623 | METHOD OF CELL-CLUSTER ANALYSIS | Chang Gung Memorial Hospital, Linkou | HAIDER, SYED | 2633 | §101 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18734819 | SEAM TAPES AND METHODS OF MAKING THE SAME | Bemis Associates, Inc. | FISCHER, JUSTIN R | 1749 | §103 | Final Rejection | — | Pending | Jun 05, 2024 |
| 18635153 | METHODS FOR REPROGRAMMING SOMATIC CELLS | Whitehead Institute For Biomedical Research | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18701596 | OPTIMIZED BIOSYNTHESIS PATHWAY FOR CANNABINOID BIOSYNTHESIS | Cellibre, Inc. | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§103§112 | Non-Final OA | 84d | Pending | Apr 15, 2024 |
| 18696878 | MIRNA COMBINATION FOR THE PREVENTION AND TREATMENT OF CANCER | Institut National De La Santé Et De La Recherche Medicale | BRETZ, COREY LANE | §102§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 | |
| 18611871 | METHOD FOR TREATING ZIKA VIRUS INFECTION WITH QUERCETIN-CONTAINING COMPOSITIONS | Quercis Pharma AG | CRAIGO, BAHAR ALAWI | 1699 | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18587684 | PURIFICATION METHOD OF MYCOBACTERIUM-DERIVED NANOCARRIER PROTEIN | Nankai University | FRONDA, CHRISTIAN L | 1656 | §103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18578949 | IMPROVED METHOD FOR PRODUCING A COMPONENT BY MEANS OF ADDITIVE MANUFACTURING | Rwth Aachen | WANG, NICHOLAS A | §112 | Non-Final OA | — | Pending | Jan 12, 2024 | |
| 18576073 | METHODS | Genetix Biotherapeutics Inc. | TSUI, YUNG-SHENG M | 1684 | §102§103 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18391648 | METHOD FOR IMPROVING DIABETIC WOUND HEALING USING MIR-200B | Hungkuang University | SAPKOTA, SURAJ | 4100 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18561857 | PRISTINAMYCIN IA AND FLOPRISTIN COMBINATIONS IN TREATING OR PREVENTING BACTERIAL INFECTIONS | Aimmax Therapeutics, Inc. | BOWLES, DAVID PAUL | 1654 | §103 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18560883 | ENGINEERED CELLS, ENZYMES, AND METHODS FOR PRODUCING CANNABINOIDS | Cellibre, Inc. | GORDON, MELENIE LEE | 1651 | §102§103§112 | Non-Final OA | 84d | Pending | Nov 14, 2023 |
| 18386551 | CHROMOSOME NEIGHBORHOOD STRUCTURES AND METHODS RELATING THERETO | Whitehead Institute For Biomedical Research | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18499169 | OPHTHALMIC DRUG DELIVERY CARRIER AND METHOD FOR PREPARING THE SAME | Chang Gung University | LIEB, JEANETTE M | 1654 | §102 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18495731 | METHODS AND COMPOSITIONS FOR IN VIVO DIRECT GENOME EDITING IN PLANTS | The Regents of the University of California | KUMAR, VINOD | 1663 | §103 | Final Rejection | 96d overdue | Pending | Oct 26, 2023 |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | The Children's Hospital of Philadelphia | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 61d | Pending | Oct 11, 2023 |
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | National Health Research Institutes | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 34d | Pending | Sep 28, 2023 |
| 18372855 | LIFTING YOKE | Danhydra A/S | VU, STEPHEN A | §112 | Non-Final OA | — | Pending | Sep 26, 2023 | |
| 18209360 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | Aveta Biomics, Inc. | PURDY, KYLE A | 1611 | §103 | Final Rejection | 63d | Pending | Jun 13, 2023 |
| 18038943 | MODULATING TRANSCRIPTIONAL CONDENSATES | Whitehead Institute For Biomedical Research | BUCHANAN, BAILEY CHEYENNE | 1682 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18035683 | METHODS | Genetix Biotherapeutics Inc. | WESTON, ALYSSA G | 1633 | §102 | Non-Final OA | 62d | Pending | May 05, 2023 |
| 18034876 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | Massachusetts Institute Of Technology | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Non-Final OA | — | Pending | May 01, 2023 |
| 18135773 | PATCH SYSTEM FOR MONITORING AND ENHANCING SLEEP AND CIRCADIAN RHYTHM ALIGNMENT | Circadian Positioning Systems, Inc. | DORNA, CARRIE R | 3791 | §101§102§103DP | Final Rejection | 60d overdue | Pending | Apr 18, 2023 |
| 18023086 | METHODS OF PREPARING IRON COMPLEXES | LG Bionano, LLC | SAEED, ALI S | 1616 | §103§112 | Non-Final OA | 23d overdue | Pending | Feb 24, 2023 |
| 18021156 | EX VIVO BRAIN TUMOR MODEL | Massachusetts Institute Of Technology | REGLAS, GILLIAN CHELSEA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 17917365 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | Tiba Biotech LLC | VIGIL, TORIANA NICHOLE | 1612 | §103 | Non-Final OA | — | Pending | Oct 06, 2022 |
| 17904035 | Progesterone Combinations | Glia, LLC | HUANG, GIGI GEORGIANA | 1613 | §103DP | Final Rejection | — | Pending | Aug 11, 2022 |
| 17878774 | CDC20 VARIANTS RESISTANT TO ANTI-MITOTIC DRUGS AND RELATED METHODS AND COMPOSITIONS | Whitehead Institute For Biomedical Research | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17783573 | ALDH3A2 INHIBITION AND FERROPTOSIS INDUCTION FOR CANCER THERAPY | Shrikanta Chattopadhyay | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | 29d | Pending | Jun 08, 2022 |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | The Children's Hospital of Philadelphia | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | — | Pending | Apr 25, 2022 |
| 17763509 | HYPERBRANCHED CATIONIC POLYMERS USEFUL AS NUCLEIC ACID DELIVERY VECTORS FOR TRANSFECTING CELLS | UNIVERSITY COLLEGE DUBLIN | BAKSHI, PANCHAM | 1623 | §103DP | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17763441 | NANOPARTICLE COMPOSITIONS FOR GENE THERAPY | UNIVERSITY COLLEGE DUBLIN | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17588038 | IN VIVO GUIDE RNA LIBRARIES AND METHODS OF MAKING THE SAME | Whitehead Institute For Biomedical Research | DHAR, MATASHA | 1632 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17540968 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | President and Fellows of Harvard College | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Dec 02, 2021 |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | The Broad Institute, Inc. | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | — | Pending | Nov 30, 2021 |
| 17611560 | METHODS OF CHARACTERIZING AND UTILIZING AGENT-CONDENSATE INTERACTIONS | Whitehead Institute For Biomedical Research | PERREIRA, MELISSA JEAN | 1618 | §103 | Non-Final OA | — | Pending | Nov 15, 2021 |
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | The University of Sydney | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 85d overdue | Pending | Nov 02, 2021 |
| 17270253 | DEVICES AND METHODS FOR ABLATING BIOLOGICAL TISSUE | In Medical Group Pty Ltd. | GUERRERO ROSARIO, ANA VERUSKA | 3794 | §103 | Final Rejection | — | Pending | Feb 22, 2021 |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | Trustees Of Boston University | GROSS, CHRISTOPHER M | 1684 | §103§112 | Non-Final OA | 53d overdue | Pending | Feb 22, 2021 |
| 17052798 | IN VIVO HOMOLOGY DIRECTED REPAIR IN HEART, SKELETAL MUSCLE, AND MUSCLE STEM CELLS | President and Fellows of Harvard College | HUDSON, AMY ROSE | 1636 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2020 |
| 17040967 | METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES | Massachusetts Institute Of Technology | PERREIRA, MELISSA JEAN | 1618 | §103 | Final Rejection | 16d | Pending | Sep 23, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial